Altimmune (ALT) Competitors $8.25 +0.07 (+0.86%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALT vs. AGIO, PTGX, IOVA, AMRX, LBPH, NAMS, IDYA, RXRX, CNTA, and APGEShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Iovance Biotherapeutics (IOVA), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Agios Pharmaceuticals Protagonist Therapeutics Iovance Biotherapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Recursion Pharmaceuticals Centessa Pharmaceuticals Apogee Therapeutics Altimmune (NASDAQ:ALT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do institutionals and insiders believe in ALT or AGIO? 78.1% of Altimmune shares are owned by institutional investors. 4.1% of Altimmune shares are owned by company insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, ALT or AGIO? Altimmune has higher earnings, but lower revenue than Agios Pharmaceuticals. Altimmune is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$52K11,284.25-$88.45M-$1.55-5.32Agios Pharmaceuticals$32.87M61.45-$352.09M$11.363.12 Does the media prefer ALT or AGIO? In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Altimmune. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 10 mentions for Altimmune. Altimmune's average media sentiment score of 0.51 beat Agios Pharmaceuticals' score of 0.31 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Agios Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ALT or AGIO? Agios Pharmaceuticals received 434 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.73% of users gave Altimmune an outperform vote while only 67.03% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAltimmuneOutperform Votes5672.73% Underperform Votes2127.27% Agios PharmaceuticalsOutperform Votes49067.03% Underperform Votes24132.97% Which has more risk and volatility, ALT or AGIO? Altimmune has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Do analysts rate ALT or AGIO? Altimmune presently has a consensus target price of $20.00, indicating a potential upside of 142.42%. Agios Pharmaceuticals has a consensus target price of $56.33, indicating a potential upside of 59.04%. Given Altimmune's stronger consensus rating and higher possible upside, equities analysts clearly believe Altimmune is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ALT or AGIO more profitable? Agios Pharmaceuticals has a net margin of 2,051.38% compared to Altimmune's net margin of -199,076.92%. Agios Pharmaceuticals' return on equity of -2.93% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-199,076.92% -55.81% -50.60% Agios Pharmaceuticals 2,051.38%-2.93%-2.58% SummaryAgios Pharmaceuticals beats Altimmune on 10 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$586.78M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-5.3210.5991.3417.19Price / Sales11,284.25195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book3.005.104.794.78Net Income-$88.45M$151.51M$120.07M$225.60M7 Day Performance-8.64%-2.15%-1.89%-1.24%1 Month Performance-2.21%-3.14%11.45%3.36%1 Year Performance4.56%11.50%30.61%16.58% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune1.9536 of 5 stars$8.25+0.9%$20.00+142.4%+3.4%$586.78M$52,000.00-5.3250News CoveragePositive NewsAGIOAgios Pharmaceuticals4.2892 of 5 stars$43.80+12.4%$56.33+28.6%+53.6%$2.50B$32.87M3.73390Analyst ForecastPTGXProtagonist Therapeutics3.5882 of 5 stars$41.42+0.8%$53.78+29.8%+100.0%$2.47B$60M15.44125News CoveragePositive NewsIOVAIovance Biotherapeutics4.0084 of 5 stars$7.89+0.8%$22.33+183.1%+2.8%$2.40B$1.19M-5.25500AMRXAmneal Pharmaceuticals2.8823 of 5 stars$7.74-1.1%$10.00+29.2%+47.1%$2.40B$2.39B-11.517,700Analyst DowngradeNews CoverageLBPHLongboard Pharmaceuticals0.6628 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020NAMSNewAmsterdam Pharma2.8064 of 5 stars$24.50-0.8%$36.20+47.8%+142.4%$2.26B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3203 of 5 stars$25.86+2.7%$53.67+107.5%-23.7%$2.24B$3.92M-10.8180Analyst ForecastRXRXRecursion Pharmaceuticals2.4142 of 5 stars$7.51+8.1%$9.25+23.2%-36.3%$2.15B$44.58M-4.85400News CoverageHigh Trading VolumeCNTACentessa Pharmaceuticals2.9987 of 5 stars$16.29-1.7%$25.83+58.6%+131.0%$2.15B$6.85M-10.8372Insider TradeAPGEApogee Therapeutics2.5994 of 5 stars$46.76+5.1%$83.88+79.4%+92.5%$2.11BN/A-18.3991 Related Companies and Tools Related Companies Agios Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Iovance Biotherapeutics Alternatives Amneal Pharmaceuticals Alternatives Longboard Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives IDEAYA Biosciences Alternatives Recursion Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
